Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer

Conclusion: This expanded 50-patient cohort of men with extensive prior therapy confirms our earlier report of high response rates, low toxicity, and improved quality of life with 177Lu-PSMA radioligand therapy. On progression, rechallenge 177Lu-PSMA demonstrated higher response rates than other systemic therapies.

Source: Journal of Nuclear Medicine - June 3, 2020 Category: Nuclear Medicine Authors: Violet, J., Sandhu, S., Iravani, A., Ferdinandus, J., Thang, S.-P., Kong, G., Kumar, A. R., Akhurst, T., Pattison, D., Beaulieu, A., Mooi, J., Tran, B., Guo, C., Kalff, V., Murphy, D. G., Jackson, P., Eu, P., Scalzo, M., Williams, S., Hicks, R. J., Hofman Tags: Clinical Source Type: research